Trial Site Detail

 

Drug:
BIIB021 (CNF2024)
Trial:
An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST) Refractory to, Intolerant of, or Not a Candidate for Imatinib and Sunitinib Treatment
Conditions: Gastrointestinal Stromal Tumor
Trial Status:
Completed

 

Vanderbilt-Ingram Cancer Center

2220 Pierce Ave.     691 Preston Building
Nashville , TN 37232
USA

 

Principal Investigator:
Vicki Keedy
Contact:
Vanderbilt-Ingram Cancer Center cancer information line 1-800-811-8480.
Activation Status of this Site:
Closed
Notes about this Site:
Vanderbilt-Ingram Cancer Center Website:
http://www.vicc.org/ct/

 

 

Navigating the Map

Use the plus (+) and minus (-) controls to zoom in/out.

Click and drag the map or use the arrows to move (pan) the map.

Tip: Click the marker before zooming and the map will stay centered on the marker as you zoom.